Cue Aerie’s stock rise.
What is Rhopressa?
1. It increases fluid outflow through the trabecular meshwork by inhibiting Rho Kinase (ROCK).
2. It reduces fluid production in the eye by inhibiting the norepinephrine transporter (NET).
3. It lowers episcleral venous pressure.
This committee’s endorsement is a preliminary review and doesn’t mean it’s FDA approved yet. A new drug application was submitted to the FDA back in February of this year. They plan to announce their decision in February 2018. Stay tuned.